Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Core Insights - Kura Oncology's KOMZIFTI (ziftomenib) is generating early revenue momentum and has received positive feedback from the market, emphasizing its differentiated safety and convenience, which supports ongoing development plans targeting up to 50% of AML patients [1][2] Financial Performance - The company reported a net product revenue of $2.1 million in Q4 2025, based on approximately five weeks of commercial sales following the FDA approval on November 13 [5][13] - Collaboration revenue for Q4 2025 was $15.2 million, a decrease from $53.9 million in Q4 2024, reflecting non-cash revenue recognition under the collaboration agreement with Kyowa Kirin [13] - The net loss for Q4 2025 was $81.0 million, compared to $19.2 million for the same period in 2024 [13] Product Development and Pipeline - KOMZIFTI has been granted full FDA approval for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [5] - The company has initiated pivotal KOMET-017 Phase 3 frontline trials evaluating ziftomenib in combination with chemotherapy for patients with NPM1-m or KMT2A-rearranged AML [4] - Multiple clinical data milestones are expected in 2026 across AML and solid tumor programs, including ziftomenib's development in gastrointestinal tumors and darlifarnib in renal cell carcinoma [2][6] Market Position and Strategy - KOMZIFTI has been added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [5] - Approximately 80% of private payers established published coverage policies for KOMZIFTI within the first 90 days of its launch, all aligned with the label and without additional restrictions [5] - The company has a strong capital position with $667.2 million in cash and equivalents, expected to support the advancement of ziftomenib through to the topline results from the first pivotal Phase 3 trial anticipated in 2028 [8][9] Future Outlook - Kura expects 2026 to be a data-rich year with multiple potential value inflection points, including ongoing enrollment in pivotal trials and the advancement of next-generation therapies [6][9] - The company aims to establish clear differentiation in the menin inhibitor class and achieve leading class share in the R/R NPM1-m AML setting [7]